I apologize for the delayed response.
By definition, a person with slow growth and short stature is defined as height below the 3rd percentile for age, growth rate <10th percentile for bone age, predicted height differ significantly from parental height, or abnormal body proportion. This definition is taken from "Short Stature in Childhood - Challenges and Choices" by Dr. David Allen and Dr. Leona Cuttler, a Clinical Practice article from The New England Journal of Medicine 2013;368:1220-8.
Your height is 165 cm, or 5 feet 5 inches. And your weight is 48 kg or 105.8 lbs.
Using ideal body weight (IBW) calculations:
Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet.
Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet
Your IBW is calculated to be 61.5 kg, so you are currently about 22% below your ideal body weight. In addition, your body mass index (BMI) is 17.6, which is considered underweight.
With your height and age, you are in the 5th percentile when plotted on the Growth Curve Chart of the Bayley-Pinneau method. So, by definition, you are not in the short stature category. However, you are considered in the underweight category.
Main causes of short stature can be divided into:
1. Idiopathic, or without any medical causes. Growth delay and/or parental genetics are the primary reasons. Most of the time, children will reach the same adult height similar to the parents.
2. Medical causes such as asthma, congenital heart disease, kidney disease, celiac disease, endocrine disorders, malnutrition, and etc. Please note this is only a partial list.
Since short stature may due to multiple causes, it is best that you consult your primary care physician and endocrinologist who specializes in growth development to determine any underlying cause or medical issues. Once we understand the root of the cause, then we can address it better.
In 2003, U.S. Food and Drug Administration (FDA) approved the use of human growth hormone to treat children with idiopathic short stature who are below the 1st growth percentile (- 2.25 SD). The projected height increase may range from 1.2 to 2.8 inches (or 3.0 to 7.1 cm), with widely varied results. The cost of treatment can range from $10,000 to $60,000 per patient per year.
Last year, based on the Santé Adulte GH Enfant study, or SAGhE, in France, FDA published a drug safety cautioning providers regarding human growth hormone therapy. The SAGhE study reported a 30% increased risk of death in patients treated with recombinant human growth hormone during childhood when compared to the general population.
As you can see, many factors need to be considered to determine if you are a good candidate for the growth treatment, along with risk vs. benefit analysis of the therapy. I hope the information provided is helpful to you and you will be able to share it with your providers. Take care and good luck!
For more information, please go to:
1. Short stature - Medline Plus
2. Short Stature in Childhood - Challenges and Choices: New England Journal of Medicine 2013
3. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline - AHRQ
4. Other reference websites:
•The Human Growth Foundation
•The MAGIC Foundation®
•The Hormone Health Network